The non-specificity of metabolic biomarkers may even be misleading (e.g., patients with pyridoxine-dependent epilepsy due to PLPBP gene mutations were misdiagnosed with mitochondrial or glycine encephalopathies due to non-specific abnormalities in metabolic testing) [48]. This evidence concerns the gene PLPBP and glycine encephalopathy.